β-catenin plus PROX1 immunostaining stratifies disease progression and patient survival in neoadjuvant-treated pancreatic cancer (English)
Free access
- New search for: Eurola, Annika
- New search for: Ristimäki, Ari
- New search for: Mustonen, Harri
- New search for: Nurmi, Anna-Maria
- New search for: Hagström, Jaana
- New search for: Kallio, Pauliina
- New search for: Alitalo, Kari
- New search for: Haglund, Caj
- New search for: Seppänen, Hanna
- New search for: Eurola, Annika
- New search for: Ristimäki, Ari
- New search for: Mustonen, Harri
- New search for: Nurmi, Anna-Maria
- New search for: Hagström, Jaana
- New search for: Kallio, Pauliina
- New search for: Alitalo, Kari
- New search for: Haglund, Caj
- New search for: Seppänen, Hanna
In:
Tumor Biology
;
44
, 1
;
69-84
;
2022
- Article (Journal) / Electronic Resource
-
Title:β-catenin plus PROX1 immunostaining stratifies disease progression and patient survival in neoadjuvant-treated pancreatic cancer
-
Additional title:β-catenin plus PROX1 immunostaining stratifies disease progression
-
Contributors:Eurola, Annika ( author ) / Ristimäki, Ari ( author ) / Mustonen, Harri ( author ) / Nurmi, Anna-Maria ( author ) / Hagström, Jaana ( author ) / Kallio, Pauliina ( author ) / Alitalo, Kari ( author ) / Haglund, Caj ( author ) / Seppänen, Hanna ( author )
-
Published in:Tumor Biology ; 44, 1 ; 69-84
-
Publisher:
- New search for: IOS Press
-
Place of publication:Amsterdam, The Netherlands
-
Publication date:2022-06-30
-
Size:16 pages
-
ISSN:
-
DOI:
-
Type of media:Article (Journal)
-
Type of material:Electronic Resource
-
Language:English
-
Keywords:
-
Licence:
-
Source:
Table of contents – Volume 44, Issue 1
The tables of contents are generated automatically and are based on the data records of the individual contributions available in the index of the TIB portal. The display of the Tables of Contents may therefore be incomplete.
- 1
-
Serological cancer-associated protein biomarker levels at bowel endoscopy: Increased risk of subsequent primary malignancyPiper, Thomas B. / Nielsen, Hans J. / Christensen, Ib Jarle et al. | 2022
- 17
-
Vitamin B12 enhances the antitumor activity of 1,25-dihydroxyvitamin D3 via activation of caspases and targeting actin cytoskeletonAtoum, Manar F. / Alzoughool, Foad E. / Al-Mazaydeh, Zainab A. / Rammaha, Majdoleen S. / Tahtamouni, Lubna H. et al. | 2022
- 37
-
Tumor-associated CD3- and CD8-positive immune cells in colorectal cancer: The additional prognostic value of CD8+-to-CD3+ ratio remains debatableKasurinen, Jussi / Hagström, Jaana / Kaprio, Tuomas / Beilmann-Lehtonen, Ines / Haglund, Caj / Böckelman, Camilla et al. | 2022
- 53
-
Bithiophene derivative induced apoptosis and suppression of Akt pathway in mouse leukemic modelAlgharib, Ali Samy / Shanab, Gamila Mohamed-Labib / Abdel-Ghaffar, Abdel-Rahman Badr / Ismail, Mohamed Ahmed / Mohamed, Rania Hassan et al. | 2022
- 69
-
β-catenin plus PROX1 immunostaining stratifies disease progression and patient survival in neoadjuvant-treated pancreatic cancerEurola, Annika / Ristimäki, Ari / Mustonen, Harri / Nurmi, Anna-Maria / Hagström, Jaana / Kallio, Pauliina / Alitalo, Kari / Haglund, Caj / Seppänen, Hanna et al. | 2022
- 85
-
β-Catenin is reduced in membranes of human prolactinoma cells and it is inhibited by temozolomide in prolactin secreting tumor modelsDemarchi, Gianina / Valla, Sofía / Perrone, Sofía / Chimento, Agustina / Bonadeo, Nadia / Vitale, Daiana Luján / Spinelli, Fiorella Mercedes / Cervio, Andrés / Sevlever, Gustavo / Alaniz, Laura et al. | 2022
- 107
-
MicroRNA-99b-5p targets mTOR/AR axis, induces autophagy and inhibits prostate cancer cell proliferationNiture, Suryakant / Tricoli, Lucas / Qi, Qi / Gadi, Sashi / Hayes, Kala / Kumar, Deepak et al. | 2022
- 129
-
Exosomes in the visual system: New avenues in ocular diseasesManukonda, Radhika / Attem, Jyothi / Yenuganti, Vengala Rao / Kaliki, Swathi / Vemuganti, Geeta K. et al. | 2022
- 153
-
Unfavorable prognosis and clinical consequences of APOBEC3B expression in breast and other cancers: A systematic review and meta-analysisJafarpour, Sima / Yazdi, Maryam / Nedaeinia, Reza / Ghobakhloo, Sepideh / Salehi, Rasoul et al. | 2022
- 171
-
CT imaging phenotypes linked to CA125 and HE4 biomarkers are highly predictive in discriminating between hereditary and sporadic ovarian cancer patientsManganaro, Lucia / Celli, Veronica / Viggiani, Valentina / Berardelli, Elena / Granato, Teresa / Tartaglione, Sara / Farina, Antonella / Catalano, Carlo / Angeloni, Antonio / Anastasi, Emanuela et al. | 2022
- 187
-
Induction of alternative NF-κB within TAg-induced basal mammary tumors in activation-resistant inhibitor of κ-B kinase (IKKα) mutant miceOuld-Brahim, Fares / Sau, Andrea / Carr, David A. / Jiang, Tianqi / Pratt, M.A. Christine et al. | 2022
- 205
-
HE4 and CA125 serum biomarker monitoring in women with epithelial ovarian cancerSamborski, Alexandra / Miller, M. Craig / Blackman, Alexandra / MacLaughlan-David, Shannon / Jackson, Amanda / Lambert-Messerlian, Geralyn / Rowswell-Turner, Rachel / Moore, Richard G. et al. | 2022
- 215
-
ErbB4-encoded novel miRNAs act as tumor suppressors by regulating ErbB/PI3K signalingGhaemi, Zahra / Soltani, Bahram M. / Mowla, Seyed Javad et al. | 2022
- 231
-
Retraction to: Long non-coding RNA TUSC7 acts a molecular sponge for miR-10a and suppresses EMT in hepatocellular carcinoma| 2022
- 233
-
Retraction to: MicroRNA-133a suppresses the proliferation, migration, and invasion of laryngeal carcinoma cells by targeting CD47| 2022
- 235
-
Erratum to: Human epididymis protein 4 expression positively correlated with miR-21 and served as a prognostic indicator in ovarian cancer| 2022
- 237
-
Erratum to: SMAD4 and its role in pancreatic cancer| 2022
- 239
-
Role of colony-stimulating factor 1 in the neoplastic process of tenosynovial giant cell tumorTap, William D. / Healey, John H. et al. | 2022
- 249
-
Predictive biomarkers for response to trametinib in non-small cell lung cancerParekh, Palak R. / Botting, Gregory M. / Thurber, Denise B. / Boruszczak, Marika / Murphy, William / Bertenshaw, Greg P. et al. | 2022